Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity

BRAF inhibitor (BRAFi) therapy is associated with the induction of neoplasia, most commonly cutaneous squamous cell carcinoma (cuSCC). This toxicity is explained in part by “paradoxical ERK activation,” or the hyperactivation of ERK signaling by BRAFi in BRAF wild-type cells. However, the rate of cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Adelmann, Charles H., Ching, Grace, Du, Lili, Saporito, Rachael C., Bansal, Varun, Pence, Lindy J., Liang, Roger, Lee, Woojin, Tsai, Kenneth Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058692/
https://www.ncbi.nlm.nih.gov/pubmed/27028853
http://dx.doi.org/10.18632/oncotarget.8351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058692/
https://www.ncbi.nlm.nih.gov/pubmed/27028853
http://dx.doi.org/10.18632/oncotarget.8351

Ejemplares similares